In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck TEA request

This article was originally published in The Rose Sheet

Executive Summary

Merck KGaA U.S. affiliate EM Industries seeks 90-day extension to convert pending citizen petition for sunscreen ingredient Eusolex 6300 into "time and extent application" for priority review. In May 21 letter to FDA, Merck counsel Buchanan Ingersoll (Washington, D.C.) says company expects to file TEA but "due to the extensive lapse of time" since petition's filing in 1980, recompiling original data "and supplementing that information with data and other relevant information generated over the last 20 years has been difficult." In April, FDA notified petitioners they have 120 days from Jan. 23 publication of "material time, material extent" rule to convert petitions into TEAs (1"The Rose Sheet" May 6, 2002, In Brief). Merck says it would consider any denial of additional time, coupled with agency's April letter, to be a "final administrative action" on the petition and would "seek relief through the judicial system"...

You may also be interested in...

Sunscreen petitions

FDA will "give priority" to reviews of time and extent applications (TEAs) submitted by firms that previously petitioned agency to include specific foreign-marketed ingredients in sunscreen monograph, FDA reiterates in six letters to ingredient suppliers and their counsel. As outlined in Jan. 23 final reg, citizen petitions must be converted to TEAs "within 120 days" of rule's publication (1"The Rose Sheet" Jan. 28, 2002, p. 9). Letters to Ciba Specialty Chemicals, EM Industries, BASF counsel and Haarmann & Reimer counsel, dated from April 19 through April 25, advise firms that agency does not "intend to take further action" on firms' respective petitions...

Strides Targets $200-400m From Generic Injectables In Mid-Term

Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Abbott Readying Vildagliptin ER In India Amid Price Competition

Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts